People lose weight on GLP-1 receptor agonists — but new data presented at ENDO 2026 suggests many of them also start moving less. A Fitbit-based cohort study found daily step counts dropped by a mean of 560 steps per day after patients started a semaglutide- or tirzepatide-class drug, with moderate-to-vigorous activity falling alongside it.
Research-context information only. Semaglutide, tirzepatide, and retatrutide are the active ingredients in FDA-approved products (or, for retatrutide, an investigational drug); research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the ENDO 2026 study found
The study — titled "Losing Pounds, Not Gaining Steps: The Paradox of GLP-1 Receptor Agonist Therapy" — was presented on June 14, 2026, at the Endocrine Society's ENDO 2026 meeting in Chicago. The lead author was Sajana Maharjan, MD, of HSHS Saint John's Hospital in Springfield, Illinois.
It was a retrospective pre-post cohort analysis built on the National Institutes of Health's All of Us Research Program. Researchers identified adults with obesity who started a GLP-1 receptor agonist and had Fitbit wearable data both before and after initiation. Of 1,950 patients prescribed a GLP-1, 753 (38.6%) had enough wearable data to analyze.
The headline numbers: mean daily steps fell from 5,047 to 4,487 — a drop of 560 steps per day (P<0.001). Moderate-to-vigorous physical activity (MVPA) declined from 27.9 to 22.2 minutes per day. In other words, as the scale moved down, daily movement moved down with it.
The findings are a conference presentation and have not yet been peer-reviewed or published in a journal, so they should be read as a signal rather than a settled conclusion. They also echo separate ENDO 2026 and earlier trial discussions about lean-mass loss on GLP-1s — the concern being that less movement plus appetite suppression can erode muscle along with fat.
What this means for people running GLP-1s
The practical takeaway from the researchers was blunt: exercise can't be treated as optional on these drugs. The study authors called for targeted interventions that keep people active alongside the medication, rather than assuming weight loss alone will translate into more movement.
For anyone sourcing GLP-1-class compounds in the research-peptide market, the activity-decline signal stacks on top of two issues already well documented in the trial literature:
- Lean-mass loss. Published GLP-1 trials report that a substantial fraction of total weight lost is lean tissue, not just fat. Lower step counts and less MVPA work in the same direction.
- Plateau and regain. Trial data show weight regain is common after stopping, and muscle is harder to rebuild than fat is to regain. Keeping activity up during the cut is the lever most under a user's control.
This is also why community protocols frequently pair GLP-1s with growth-hormone secretagogues. Tesamorelin and ipamorelin (often with CJC-1295) show up repeatedly in self-reported GLP-1 stacks aimed at preserving lean tissue and supporting recovery during a calorie deficit. None of that replaces resistance training and protein — the trial-supported foundations — but it's the most common peptide-layer addition users describe.
If you're comparing where to source these compounds, live $/mg pricing across recommended vendors sits on the /best/semaglutide, /best/tirzepatide, and /best/retatrutide pages, and current coupons are aggregated on the /deals page.
